Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
AACR 2023 – Moderna's immunotherapeutic splash
EP Vantage
Wed, 03/22/23 - 10:03 am
AACR
Moderna Therapeutics
Allogene
AstraZeneca
Merck
Roche
Novartis
Eli Lilly
Innovent
Springworks
Biogene
Relay Therapeutics
Vivace Therapeutics
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
NASDAQ
Mon, 03/20/23 - 04:47 pm
Novartis
SMA
Zolgensma
gene therapy
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
BioSpace
Mon, 03/20/23 - 09:51 am
Sangamo Therapeutics
Novartis
Biogen
neurology
gene regulation therapies
Novartis' Tafinlar/Mekinist combo scores new indication in pediatric brain cancer
Endpoints
Sun, 03/19/23 - 01:36 pm
Novartis
Tafinlar
Mekinist
pediatric
brain cancer
FDA
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Sat, 03/18/23 - 03:37 pm
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Sat, 03/18/23 - 03:35 pm
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift
BioSpace
Wed, 03/15/23 - 11:17 am
Mediar Therapeutics
Novartis
Pfizer
fibrosis
After $3.4B deal and EU withdrawal, Novartis looks to sell Xiidra
Fierce Pharma
Tue, 03/14/23 - 11:30 am
Novartis
Xiidra
ophthalmology
Seeking to boost shareholder returns, Novartis readies new $11B buyback round
Fierce Pharma
Mon, 03/13/23 - 04:42 pm
Novartis
share repurchase
Sandoz, betting on biosimilar sales, to build new production plant
BioPharma Dive
Thu, 03/9/23 - 09:15 pm
Sandoz
Novartis
drug manufacturing
Slovenia
biosimilars
Amid major restructuring, Novartis CEO Narasimhan’s 2022 pay fell by more than a quarter
Fierce Pharma
Wed, 03/8/23 - 09:51 am
Novartis
Pharma CEOs
Vas Narasimhan
executive pay
restructuring
Novartis ready to head for deep space with Voyager after a year 'kicking the tires'
Fierce Biotech
Mon, 03/6/23 - 11:41 am
Novartis
Voyager Therapeutics
Novartis takes step toward expanding supply of in-demand cancer drug
Biopharma Dive
Sun, 03/5/23 - 03:09 pm
Novartis
Pluvicto
prostate cancer
Spotlight – What is next in Nash
EP Vantage
Fri, 03/3/23 - 10:02 am
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Go or no go? Vaccines and neurology up for discussion
EP Vantage
Tue, 02/28/23 - 11:05 am
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
Fulcrum's clinical hold caps off tough week for sickle cell drug development
Fierce Biotech
Sun, 02/26/23 - 10:20 pm
Fulcrum Therapeuticsl
FDA
sickle cell disease
clinical trials
FDX-6058
Novartis
Sangamo
Graphite Bio
Novartis backs away from NASH, furthering its research revamp
BioPharma Dive
Sun, 02/26/23 - 10:16 pm
Novartis
NASH
Pliant Therapeutics
PLN-1474
Novartis Drops SCD Gene Therapy Program with Intellia
BioSpace
Fri, 02/24/23 - 09:03 am
Novartis
sickle cell disease
Intellia Therapeutics
CRISPR
gene editing
Novartis, Roche avoid $475M antitrust fine in French appeals court
Fierce Pharma
Mon, 02/20/23 - 12:57 pm
Novartis
Roche
antitrust
Lucentis
Novartis loses $940M arbitration case against Mitsubishi Chemical over Gilenya royalties
Fierce Pharma
Mon, 02/20/23 - 12:42 pm
Novartis
Mitsubishi Chemical
multiple sclerosis
MS
Supreme Court
legal
patents
Gilenya
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »